Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma

NCT06149260 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.

NCT NCT06149260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06149260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-lable Trial of Subcutaneous Semaglutide in Systemic Scleroderma
Lead sponsor
Second Xiangya Hospital of Central South University
Phase
Phase 1
Overall status
Unknown status
Start date
February 29, 2024
Completion date
December 31, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, scleroderma, systemic, semaglutide